Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study

Next Previous
Search
Trial Profile

MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms MIRACLE

    • Most Recent Events

    • 15 Jun 2024 Results(n=60) studying efficacy and safety of reduced dose of methotrexate in combination with adalimumab comparing to maximum tolerated dose of methotrexate in EORA , presented at the 25th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Primary endpoint has not been met (Simple Disease Activity Index (SDAI) Remission Rate (ADA/MTX-Reduced Dose Group)) , according to Results presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Primary endpoint has not been met (Simple Disease Activity Index (SDAI) Remission Rate (ADA/MTX-Maximum Tolerated Dose Group)) , according to Results presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top